Clinical Trial Information
Mitsubishi Tanabe Pharma Corporation (herein after MTPC) is working to increase transparency in clinical trial information. For details, please click here to access our Clinical Trial Information Disclosure Policy.
This website provides information related to summaries of clinical trial information, clinical trial summary results, clinical trial data to be shared with researchers, publication, and clinical trial data to be shared with patients.
- Terms of Use
-
The information on this web page is not intended to promote or advertise MTPC products, or to recommend off-label or unapproved use of any product.
MTPC will endeavor to update information regularly on all clinical trials listed here. However, please understand that changes in clinical trial results may not always be reflected immediately in the list of summaries of clinical trial information provided on this web page.
Please note: Each individual patient is unique, and information from a specific clinical trial may be more clinically significant for some patients than for others. This clinical significance should be determined by doctors experienced in treating the specific disease that was targeted in the trial, or by other qualified healthcare professionals. If you are a patient or family member and you have any questions about the relevance of clinical trial results to your specific symptoms, please consult your doctor or other appropriate healthcare professional.
1. Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
MTPC will register and disclose information on publicly-accessible clinical trial registries such as ClinicalTrials.gov, JapicCTI, EU Clinical Trials Register regarding clinical trials that are being conducted or have been conducted. These three registries can be viewed through the links
below:
b. Disclosure of clinical trial summary results
MTPC will disclose summaries of clinical study reports outlining trials conducted in patients, and will also provide simplified summary results that can be easily understood by patients and other non-specialists.
MTPC will disclose the results from clinical trials in patients that form part of the submission package for products initially approved in the United States, Europe, or Japan (in all areas where MTPC intends to obtain marketing approval) in or after January 2018. Results will not be disclosed if MTPC decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.
Summary results in plain language are currently under preparation.
c. List of summaries of clinical trial information
Summary of clinical trial information disclosed on ClinicalTrials.gov, and summary results for each clinical trial are provided in the list of summaries of clinical trial information below.
The list does not contain clinical trial information on JapicCTI which is written in Japanese.
| Development code (Generic name) |
Study No. | Study Title | Indication | Information on ClinicalTrials.gov | Summary results | Summary results in plain language | |
|---|---|---|---|---|---|---|---|
| ClinicalTrials.gov | Study Status | ||||||
| MT-1186 (Edaravone) |
MT-1186-A03 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | ALS | NCT04577404(Registration Oct 2020) | Not yet recruiting | ||
| MT-1186 (Edaravone) |
MT-1186-A02 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | ALS | NCT04569084(Registration Sep 2020) | Not yet recruiting | ||
| MT-7117 (Dersimelagon) |
MT-7117-G02 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | NCT04440592(Update Aug 2020) | Not yet recruiting | ||
| MT-7117 (Dersimelagon) |
MT-7117-G01 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria | EPP, XLP | NCT04402489 (Update Sep 2020) | Recruiting | ||
| MT-1186 (Edaravone) |
MT-1186-J05 | Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy | Japanese Patients With ALS | NCT04254913 (Update Oct 2020) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A4 | Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes | Type 2 Diabetes | NCT00628212 (Update May 2013) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A5 | Monotherapy Study of MP-513 in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT00998881 (Update Feb 2014) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A6 | Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT00974090 (Update May 2014) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A7 | Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT01026194 (Update Jan 2014) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A8 | Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients | Type 2 Diabetes Mellitus | NCT02314637 (Update Aug 2015) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A12 | Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT01072331 (Update Apr 2013) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A14 | Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT01301833 (Update Nov 2015) | Completed | ||
| MP-513 (Teneligliptin) |
3000-A15 | Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT02081599 (Update Sep 2017) | Completed | ||
| MP-513 (Teneligliptin) |
MP-513-C02 | Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT02916706 (Update Nov 2018) | Completed | ||
| MP-513 (Teneligliptin) |
MP-513-C03 | Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT02924064 (Update Nov 2018) | Completed | ||
| MP-513 (Teneligliptin) |
MP-513-E07 | Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT00971243 (Update Sep 2014) | Completed | ||
| GMK-527 (Alteplase〔genetical recombination〕) |
527-0611 | Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Japan Alteplase Clinical Trial II:J-ACT II) | Stroke | NCT00412867 (Update Jan 2018) | Completed | ||
| MP-214 (Cariprazine) |
A002-A3 | Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia | Schizophrenia | NCT00862992 (Update Sep 2009) | Completed | ||
| MP-214 (Cariprazine) |
A002-A4 | Safety and Efficacy of MP-214 in Patients With Schizophrenia | Schizophrenia | NCT01625000 (Update Sep 2016) | Completed | ||
| MP-214 (Cariprazine) |
A002-A5 | Long-Term Study of MP-214 in Patients With Schizophrenia | Schizophrenia | NCT01626872 (Update Apr 2017) | Completed | ||
| MP-214 (Cariprazine) |
A002-A7 | A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia | Schizophrenia | NCT01625897 (Update Apr 2015) | Completed | ||
| MP-214 (Cariprazine) |
A002-A8 | A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia | Schizophrenia | NCT01626885 (Update Jan 2015) | Completed | ||
| MP-214 (Cariprazine) |
A002-A11 | A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia | Schizophrenia | NCT01626859 (Update Jun 2014) | Completed | ||
| MCI-9038 (Argatroban) |
ARG-E07 | Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II | Heparin-induced Thrombocytopenia Type II | NCT00861692 (Update Aug 2016) | Completed | ||
| BK1310 | BK1310-J01 | Phase 3 Study of BK1310 in Healthy Infants | Immunization; Infection | NCT02992925 (Update Feb 2019) | Completed | ||
| BK1310 | BK1310-J02 | Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants | Immunization | NCT03188692 (Update Feb 2019) | Completed | ||
| BK1310 | BK1310-J03 | Confirmatory Study of BK1310 in Healthy Infants | Tetanus|Diphtheria|Pertussis|Poliomyelitis|Bacterial Meningitis | NCT03891758 (Update May 2020) | Active, not recruiting | ||
| BK1301 | BKD1A | Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents | Diphtheria|Tetanus|Pertussis | NCT02118961 (Update Jan 2017) | Completed | ||
| FTY720 (Fingolimod hydrochloride) |
CFTY720D1201 | Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS) | Multiple Sclerosis | NCT00537082 (Update Apr 2011) | Completed | ||
| FTY720 (Fingolimod hydrochloride) |
CFTY720D1201E1 | An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | NCT00670449 (Update Sep 2013) | Completed | ||
| MP-424 (Telaprevir) |
G060-A3 | Safety and PK Study of MP-424 to Treat Chronic Hepatitis C | Chronic Hepatitis C | NCT00591214 (Update May 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A5 | A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C | Hepatitis C | NCT00630058 (Update May 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A6 | Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naive Patients With Chronic Hepatitis C | Hepatitis C | NCT00780416 (Update May 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A7 | Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C | Hepatitis C | NCT00621296 (Update May 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A8 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy | Chronic Hepatitis C | NCT00780910 (Update May 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A9 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy | Hepatitis C | NCT00781274 (Update May 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A10 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients | Chronic Hepatitis C | NCT01466192 (Update Nov 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A11 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients | Chronic Hepatitis C | NCT01468584 (Update Nov 2014) | Completed | ||
| MP-424 (Telaprevir) |
G060-A12 | Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naive or Relapsed Hepatitis C | Chronic Hepatitis C (CHC) | NCT01753557 (Update Oct 2016) | Completed | ||
| MP-424 (Telaprevir) |
G060-F1 | Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naive or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) | Chronic Hepatitis C(CHC) | NCT01753570 (Update Oct 2018) | Completed | ||
| MP-424 (Telaprevir) |
MP-424-K01 | Clinical Pharmacology Study of MP-424 | Chronic Hepatitis C | NCT01766167 (Update Jan 2017) | Completed | ||
| MP-146 | KRM-306 | A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) | Chronic Kidney Disease | NCT00500682 (Update Mar 2015) | Completed | ||
| MP-146 | KRM-307 | A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) | Chronic Kidney Disease | NCT00501046 (Update Mar 2015) | Completed | ||
| MCC-257 | MCC-257-A03 | Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy | Diabetic Polyneuropathy | NCT00307749 (Update Dec 2007) | Completed | ||
| MCI-186 (Edaravone) |
MCI186-13 | Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke | Cerebral Infarction | NCT00200356 (Update Jan 2013) | Completed | ||
| MCI-186 (Edaravone) |
MCI186-16 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | NCT00330681 (Update May 2017) | Completed | ||
| MCI-186 (Edaravone) |
MCI186-17 | Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | NCT00424463 (Update Aug 2018) | Completed | ||
| MCI-186 (Edaravone) |
MCI186-18 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III | Amyotrophic Lateral Sclerosis (ALS) | NCT00415519 (Update Dec 2017) | Completed | ||
| MCI-186 (Edaravone) |
MCI186-19 | Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | NCT01492686 (Update Dec 2018) | Completed | ||
| MCI-186 (Edaravone) |
MCI-186-J20 | Dose Finding Study of MCI-186 in Acute Ischemic Stroke | Acute Ischemic Stroke | NCT03346538 (Update Sep 2018) | Terminated | ||
| MCI-186 (Edaravone) |
MCI-186-E04 | Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke | Acute Ischemic Stroke (AIS) | NCT00821821 (Update May 2014) | Completed | ||
| MT-1186 (Edaravone) |
MT-1186-A01 | Safety Study of Oral Edaravone Administered in Subjects With ALS | ALS | NCT04165824 (Update Oct 2020) | Active, not recruiting | ||
| MT-1186 (Edaravone) |
MT-1186-J04 | Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis | Japanese Patients With ALS | NCT04176224 (Registration Nov 2019) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI196-19 | Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes | Type 2 Diabetes | NCT00497198 (Update Jun 2012) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-A05 | A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia | Chronic Kidney Disease|Dialysis|Hyperphosphatemia | NCT00506441 (Update Sep 2014) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-A06 | Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia | Chronic Kidney Disease|Dialysis|Hyperphosphatemia | NCT00772382 (Update Sep 2014) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E07 | A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia | Chronic Kidney Disease|Hyperphosphatemia | NCT00416520 (Update Nov 2014) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E08 | A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia | Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Dyslipidemia | NCT00542386 (Update Oct 2014) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E09 | A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia | Chronic Kidney Disease|Dialysis|Hyperphosphatemia | NCT00451295 (Update Nov 2011) | Terminated | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E10 | A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia | Chronic Kidney Disease|Dialysis|Hyperphosphatemia | NCT00542815 (Update Oct 2014) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E11 | Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis | Chronic Kidney Disease | NCT00858637 (Update Dec 2014) | Completed | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E14 | Dose-finding Study of MCI-196 | Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Paediatric | NCT01814904 (Update May 2015) | Terminated | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E15 | Long-term Extension Study of MCI-196 | Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Paediatric | NCT01814917 (Update May 2015) | Terminated | ||
| MCI-196 (Colestimide/ Colestilan) |
MCI-196-E16 | Safety and Tolerability Study of MCI-196 | Chronic Kidney Disease|Not on Dialysis|Hyperphosphatemia|Paediatric | NCT01818687 (Update May 2015) | Terminated | ||
| MCI-9042 (Sarpogrelate) |
MCI9042-15 | Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS) | Cerebral Infarction | NCT00129805 (Update Aug 2008) | Completed | ||
| MCI-9042 (Sarpogrelate) |
MCI9042-17 | Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study | Cerebral Infarction | NCT00147303 (Update Apr 2015) | Completed | ||
| MP-435 | MP-435-J04 | Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | NCT01143337 (Update Oct 2014) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-E03 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease | Inflammatory Bowel Disease | NCT01666327 (Update Sep 2014) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-E04 | Dose-finding Study of MT-1303 | Relapsing-remitting Multiple Sclerosis | NCT01742052 (Update Sep 2016) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-E05 | Extension Study of MT-1303 | Relapsing-remitting Multiple Sclerosis | NCT01890655 (Update Apr 2016) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-E06 | Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Plaque Psoriasis | NCT01987843 (Update Dec 2014) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-E13 | Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease | Crohn's Disease | NCT02378688 (Update Oct 2016) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-E14 | Extension Study of MT-1303 in Subjects With Crohn's Disease | Crohn's Disease | NCT02389790 (Update Sep 2017) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-J02 | Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease | Crohn's Disease | NCT02148185 (Update Sep 2014) | Completed | ||
| MT-1303 (Amiselimod) |
MT-1303-J03 | Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients | Systemic Lupus Erythematosus | NCT02307643 (Update Jun 2017) | Completed | ||
| MT-2301 | MT-2301-J01 | Exploratory Clinical Study of MT-2301 | Haemophilus Influenza Type b | NCT02140047 (Update Oct 2015) | Completed | ||
| MT-2412 (Teneligliptin,Canagliflozin) |
MT-2412-J01 | Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT02220907 (Update Nov 2018) | Completed | ||
| MT-2412 (Teneligliptin,Canagliflozin) |
MT-2412-J02 | Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) | Type 2 Diabetes Mellitus | NCT02354222 (Update Nov 2018) | Completed | ||
| MT-2412 (Teneligliptin,Canagliflozin) |
MT-2412-J03 | Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) | Type 2 Diabetes Mellitus | NCT02354235 (Update Nov 2018) | Completed | ||
| MT-2990 | MT-2990-A01 | Safety and Efficacy Study of MT-2990 in Women With Endometriosis | Endometrial Related Pain | NCT03840993 (Update Sep 2020) | Recruiting | ||
| MT-2990 | MT-2990-J01 | A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients | Seasonal Allergic Rhinitis | NCT03570957 (Update Jan 2019) | Completed | ||
| MT-3921 | MT-3921-G01 | Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury | Spinal Cord Injury | NCT04096950 (Update Aug 2020) | Recruiting | ||
| MT-3995 (Apararenone) |
MT-3995-E06 | A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria | Diabetic Nephropathy | NCT01756703 (Update Feb 2015) | Completed | ||
| MT-3995 (Apararenone) |
MT-3995-E07 | A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR | Diabetic Nephropathy | NCT01756716 (Update Feb 2015) | Completed | ||
| MT-3995 (Apararenone) |
MT-3995-J03 | Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy | Diabetic Nephropathy | NCT01889277 (Update Jan 2015) | Completed | ||
| MT-3995 (Apararenone) |
MT-3995-J04 | Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy | Diabetic Nephropathy | NCT02205372 (Update Sep 2015) | Completed | ||
| MT-3995 (Apararenone) |
MT-3995-J05 | Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy | Diabetic Nephropathy | NCT02517320 (Update Mar 2017) | Completed | ||
| MT-3995 (Apararenone) |
MT-3995-J06 | An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy | Diabetic Nephropathy | NCT02676401 (Update Sep 2017) | Completed | ||
| MT-3995 (Apararenone) |
MT-3995-J07 | Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) | NASH | NCT02923154 (Update Sep 2019) | Completed | ||
| MT-5199 (Valbenazine) |
MT-5199-J02 | Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia | Tardive Dyskinesia | NCT03176771 (Update Oct 2020) | Completed | ||
| MT-5547 (Fasinumab) |
MT-5547-J01 | Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain | Osteoarthritis, Knee / Osteoarthritis, Hip | NCT03245008 (Update Oct 2019) | Active, not recruiting | ||
| MT-5625 | MT-5625-01 | Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants | Healthy | NCT03507738 (Update Aug 2019) | Completed | ||
| MT-6548 (Vadadustat) |
MT-6548-J01 | Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan | Anemia; Non-dialysis Dependent Chronic Kidney Disease | NCT03329196 (Update Oct 2019) | Completed | ||
| MT-6548 (Vadadustat) |
MT-6548-J02 | Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan | Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease | NCT03402386 (Update Mar 2019) | Completed | ||
| MT-6548 (Vadadustat) |
MT-6548-J03 | Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan | Anemia; Hemodialysis Dependent Chronic Kidney Disease | NCT03439137 (Update Oct 2019) | Completed | ||
| MT-6548 (Vadadustat) |
MT-6548-J04 | Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan | Anemia; Hemodialysis Dependent Chronic Kidney Disease | NCT03461146 (Update Mar 2019) | Completed | ||
| MT-7117 (Dersimelagon) |
MT-7117-A01 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria (EPP) | NCT03520036 (Update Sep 2020) | Completed | ||
| MT-8554 (Elismetrep) |
MT-8554-A01 | MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women | Menopause Hot Flashes | NCT03291067 (Update Oct 2019) | Completed | ||
| MT-8554 (Elismetrep) |
MT-8554-A02 | Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms | Vasomotor Symptoms (VMS) | NCT03541200 (Update Jan 2020) | Completed | ||
| MT-8554 (Elismetrep) |
MT-8554-E04 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms | Vasomotor Symptoms | NCT02803268 (Update Feb 2017) | Completed | ||
| MT-8554 (Elismetrep) |
MT-8554-E06 | Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy | Painful Diabetic Peripheral Neuropathy | NCT03172598 (Update Aug 2018) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-13 | Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | NCT00691028 (Update Mar 2014) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-19 | Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD) | Crohn's Disease | NCT00805766 (Update Feb 2018) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-20 | Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease | Pediatric Crohn's Disease | NCT01580670 (Update Jul 2019) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-21 | Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis | Pediatric Ulcerative Colitis | NCT01585155 (Update Nov 2019) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-22 | Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease | Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin | NCT01596335 (Update Oct 2018) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-23 | Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions | Behcet's Disease|Behcet Syndrome|Neuro-Behcet's Disease | NCT01532570 (Update Dec 2016) | Completed | ||
| TA-650 (Infliximab [recombinant]) |
TA-650-24 | A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis | Plaque Psoriasis|Psoriatic Arthritis|Pustular Psoriasis (Excluding a Localized)|Psoriatic Erythroderma | NCT01680159 (Update Mar 2017) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-02 | Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients | Type 2 Diabetes Mellitus | NCT00707954 (Update Apr 2014) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-04 | An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT01022112 (Update Jun 2014) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-05 | Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | NCT01413204 (Update Jun 2014) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-06 | Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT01387737 (Update Jun 2014) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-07 | A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment | Type 2 Diabetes Mellitus | NCT01512849 (Update Jun 2014) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-11 | Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT02220920 (Update Dec 2016) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-12 | Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT02227849 (Update Apr 2019) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-13 | Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | NCT02622113 (Update Apr 2019) | Completed | ||
| TA-7284 (Canagliflozin) |
TA-7284-14 | Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy | Diabetic Nephropathy | NCT03436693 (Update Apr 2020) | Active, not recruiting | ||
| TAU-284 (Bepotastine) |
TAU-284-17 | A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis | Perennial Allergic Rhinitis | NCT01425632 (Update Dec 2015) | Completed | ||
| TAU-284 (Bepotastine) |
TAU-284-18 | A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis | Perennial Allergic Rhinitis | NCT01900054 (Update Apr 2016) | Completed | ||
| TAU-284 (Bepotastine) |
TAU-284-19 | A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis | Dermatitis|Atopic | NCT01840605 (Update May 2018) | Completed | ||
| TAU-284 (Bepotastine) |
TAU-284-20 | The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis | Perennial Allergic Rhinitis | NCT01861522 (Update Dec 2015) | Completed | ||
2. Sharing Clinical Trial Data with Researchers
When requested by a qualified researcher in the field of science or medicine, MTPC will share clinical trial data that was collected from individual patients in a clinical trial with that researcher after a review committee of experts determines that such sharing is appropriate. Such clinical data will always be anonymized before sharing. MTPC will not share data that MTPC feels may place the patient at risk of being identified.
MTPC will share patient data from clinical trials in patients that form part of the submission package for products initially approved in the United States, Europe, or Japan (in all areas where MTPC intends to obtain marketing approval) in or after January 2018. Please use the following link for other conditions and limitations.
https://vivli.org/ourmember/mitsubishi-tanabe-pharma/
Researchers: Please use the link below to request data sharing.
3. Publication of Clinical Trial Results
MTPC in a timely manner, will endeavor to provide relevant presentations at scientific meetings, or publications in scientific journals, of the clinical trial results where results are considered to be of significant medical importance. When such an article is published, MTPC will cite the publication on publicly accessible clinical trial registries.
4. Sharing Clinical Trial Results with Patients Who Participate in Clinical Trials
MTPC plans to share personal patient results from clinical trials individually with each clinical trial participant. This information-sharing program is currently in the planning stages.
- Questions
-
If you have any questions about disclosure of clinical trial information, please email us: